– UK, London – OKYO Pharma Limited (LON: OKYO) today announced the appointment of Bernard Denoyer to its Board as a non-executive director with immediate effect.
“We are delighted that Bernard has joined the Board of OKYO. His expertise will be of great value to us at a very important time for the group,” commented Board Chairman, Gabriele Cerrone.
Mr Denoyer will join the Nomination Committee as its chair.
About Bernard F. Denoyer
Bernard Denoyer has 49 years of financial management experience including his service as SVP, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA approval and his retirement in June 2017.
From January 2004 until January 2013. Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc., (OTCMKTS: CLSP). While with SGYP and CLSP he supported over $500M of public and PIPE financings with related due diligence, SEC registrations and market listings.
From October 2000 to December 2003, Mr. Denoyer was an independent consultant, providing interim CFO and other services to emerging businesses, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000, Mr. Denoyer served as CFO and SVP of META Group, Inc., (NASDAQ: METG), an information technology research company.
Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honors from Columbia Business School in 1972, and a BA in Economics from Fairfield University in 1969.
Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He served in U.S. Army in Vietnam from 1969 to 1971 and has been an adjunct accounting professor at Fairfield University and the Marymount College. He is currently serving on the Board of Trustees for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc.
About OKYO
OKYO Pharma Limited is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
For more information : https://www.okyopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
